Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Vivo Capital, LLC 13F Holdings -- Portfolio & Top Positions (2026-06-30)

Vivo Capital, LLC (CIK 1674712) reported $1.10B across 47 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: TRVI ($95.0M, 8.68%), PRAX ($90.8M, 8.29%), ERAS ($75.6M, 6.90%), AVBP ($58.4M, 5.34%), ABVX ($55.3M, 5.05%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1TRVITrevi Therapeutics Inc$95.0M8.68%5.1MHold
2PRAXPraxis Precision Medicines$90.8M8.29%271,116Trimmed
3ERASErasca Inc$75.6M6.90%4.1MTrimmed
4AVBPArrivent BioPharma Inc$58.4M5.34%1.7MAdded
5ABVXAbivax SA - ADR$55.3M5.05%414,899Added
6TNGXTango Therapeutics Inc$43.1M3.94%1.4MTrimmed
7CRVSCorvus Pharmaceuticals Inc$41.9M3.83%2.8MHold
8DRUGBright Minds Biosciences Inc$39.1M3.57%557,172Hold
9SVASinovac Biotech Ltd.$38.2M3.49%5.9MHold
10TENXTenax Therapeutics Inc$36.4M3.32%2.5MAdded
11ACRSAclaris Therapeutics, Inc.$35.4M3.23%6.7MAdded
12DYNDyne Therapeutics Inc$34.6M3.16%1.6MHold
13DNTHDianthus Therapeutics Inc$34.5M3.15%353,998Hold
14ANROAlto Neuroscience Inc$31.9M2.91%1.2MAdded
15DBVTDBV Technologies SA$30.3M2.76%1.8MTrimmed
16SABSSAB Biotherapeutics Inc$28.5M2.60%7.3MTrimmed
17MLTXMoonlake Immunotherapeutics$27.3M2.49%1.4MAdded
18LBRXLB Pharmaceuticals Inc$26.0M2.37%800,000Hold
19NERVMinerva Neurosciences Inc$24.0M2.19%4.3MHold
20DSGNDesign Therapeutics Inc$23.3M2.13%1.6MHold
21ORICOric Pharmaceuticals Inc$20.0M1.83%1.8MHold
22CAMPCAMP4 Therapeutics Corporation$18.6M1.69%4.2MHold
23SNSEFaeth Therapeutics Inc$18.1M1.65%722,020Hold
24ACHVAchieve Life Sciences Inc.$18.0M1.64%2.8MNew
25CMPXCompass Therapeutics Inc$17.0M1.55%7.8MTrimmed

Source: SEC Form 13F filings · as of 2026-06-30